PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25445786-3 2015 In the present work we report the role of one of the least explored Sirtuin viz., SIRT7, under conditions of genomic stress when treated with doxorubicin. Doxorubicin 142-153 sirtuin 7 Homo sapiens 82-87 25445786-6 2015 SIRT7 overexpressing cells when treated with low dose of doxorubicin (0.25 microM) showed delayed onset of senescence, lesser accumulation of DNA damage marker gammaH2AX and lowered levels of growth arrest markers viz., p53 and p21 when compared to doxorubicin treated control GFP expressing cells. Doxorubicin 57-68 sirtuin 7 Homo sapiens 0-5 25445786-6 2015 SIRT7 overexpressing cells when treated with low dose of doxorubicin (0.25 microM) showed delayed onset of senescence, lesser accumulation of DNA damage marker gammaH2AX and lowered levels of growth arrest markers viz., p53 and p21 when compared to doxorubicin treated control GFP expressing cells. Doxorubicin 57-68 tumor protein p53 Homo sapiens 220-223 25445786-6 2015 SIRT7 overexpressing cells when treated with low dose of doxorubicin (0.25 microM) showed delayed onset of senescence, lesser accumulation of DNA damage marker gammaH2AX and lowered levels of growth arrest markers viz., p53 and p21 when compared to doxorubicin treated control GFP expressing cells. Doxorubicin 57-68 H3 histone pseudogene 16 Homo sapiens 228-231 25445786-6 2015 SIRT7 overexpressing cells when treated with low dose of doxorubicin (0.25 microM) showed delayed onset of senescence, lesser accumulation of DNA damage marker gammaH2AX and lowered levels of growth arrest markers viz., p53 and p21 when compared to doxorubicin treated control GFP expressing cells. Doxorubicin 249-260 sirtuin 7 Homo sapiens 0-5 25445786-8 2015 When treated with higher dose of doxorubicin (>1 microM), SIRT7 conferred resistance to apoptosis by attenuating stress activated kinases (SAPK viz., p38 and JNK) and p53 response thereby shifting the cellular fate towards senescence. Doxorubicin 33-44 sirtuin 7 Homo sapiens 61-66 25445786-8 2015 When treated with higher dose of doxorubicin (>1 microM), SIRT7 conferred resistance to apoptosis by attenuating stress activated kinases (SAPK viz., p38 and JNK) and p53 response thereby shifting the cellular fate towards senescence. Doxorubicin 33-44 mitogen-activated protein kinase 9 Homo sapiens 142-146 25445786-8 2015 When treated with higher dose of doxorubicin (>1 microM), SIRT7 conferred resistance to apoptosis by attenuating stress activated kinases (SAPK viz., p38 and JNK) and p53 response thereby shifting the cellular fate towards senescence. Doxorubicin 33-44 mitogen-activated protein kinase 14 Homo sapiens 153-156 25445786-8 2015 When treated with higher dose of doxorubicin (>1 microM), SIRT7 conferred resistance to apoptosis by attenuating stress activated kinases (SAPK viz., p38 and JNK) and p53 response thereby shifting the cellular fate towards senescence. Doxorubicin 33-44 mitogen-activated protein kinase 8 Homo sapiens 161-164 25445786-8 2015 When treated with higher dose of doxorubicin (>1 microM), SIRT7 conferred resistance to apoptosis by attenuating stress activated kinases (SAPK viz., p38 and JNK) and p53 response thereby shifting the cellular fate towards senescence. Doxorubicin 33-44 tumor protein p53 Homo sapiens 170-173 25445786-10 2015 SIRT7 mediated resistance to doxorubicin induced apoptosis and senescence was lost when p53 level was restored by nutlin treatment. Doxorubicin 29-40 sirtuin 7 Homo sapiens 0-5 25445786-10 2015 SIRT7 mediated resistance to doxorubicin induced apoptosis and senescence was lost when p53 level was restored by nutlin treatment. Doxorubicin 29-40 tumor protein p53 Homo sapiens 88-91